Format

Send to:

Choose Destination
See comment in PubMed Commons below
Future Virol. 2009 Nov 1;4(6):605.

Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Author information

  • 1Department of Genetics, Cell Biology & Development, University of Minnesota, Minneapolis, MN 55455, USA Tel.: +1 414 702 7232, hultq014@umn.edu.

Abstract

At least two human APOBEC3 proteins - APOBEC3F and APOBEC3G - are capable of inhibiting HIV-1 replication by mutation of the viral cDNA. HIV-1 averts lethal restriction through its accessory protein Vif, which targets these APOBEC3 proteins for proteasomal degradation. The life-or-death interaction between human APOBEC3 proteins and HIV-1 Vif has stimulated much interest in developing novel therapeutics aimed at altering the deaminase activity of the APOBEC3s, thus changing the virus' mutation rate to either lethal or suboptimal levels. The current state of mechanistic information is reviewed and the possible risks and benefits of increasing (via hypermutation) or decreasing (via hypomutation) the HIV-1 mutation rate through APOBEC3 proteins are discussed.

PMID:
20174454
[PubMed]
PMCID:
PMC2822356
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk